Valuation: Ventripoint Diagnostics Ltd.

Market Cap 19.1M 13.87M 11.88M 11.12M 10.18M 1.33B 19.35M 131M 51.23M 667M 52.09M 50.96M 2.21B P/E 2024
-3.22x
P/E 2025 -7.24x
Enterprise Value 21.66M 15.73M 13.47M 12.61M 11.54M 1.5B 21.94M 149M 58.08M 756M 59.06M 57.78M 2.5B EV / Sales 2024
187x
EV / Sales 2025 145x
Free-Float
98.38%
Yield 2024 *
-
Yield 2025 -
08-12 Ventripoint Diagnostics Ltd Expands Subscription Access For FDA-Cleared AI Cardiac Imaging Platform VMS+ 4.0 CI
08-05 UniDoc Health Corp. And Ventripoint Diagnostics Ltd. Sign MOU To Evaluate Scalable Remote Cardiac Assessment And Screening Platform CI
07-29 Ventripoint Diagnostics Ltd. Announces the Appointment of Philip M. Toleikis to its Board of Directors CI
07-20 Ventripoint Diagnostics Selects VMS+ Technology For Use In AIRES Clinical Research Study CI
06-15 Ventripoint Diagnostics Ltd. and Global Congenital Heart Disease Alliance Announce Support for Global Congenital Heart Disease Alliance CI
05-27 Ventripoint Diagnostics Ltd. - Shareholder/Analyst Call
05-21 Ventripoint Diagnostics Ltd. announced that it has received CAD 0.30803 million in funding CI
05-01 Ventripoint Diagnostics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
04-30 Ventripoint Diagnostics Ltd. Auditor Raises 'Going Concern' Doubt CI
04-28 Ventripoint Diagnostics Ltd. Announces Its Strategic Partner, Lishman Global Inc. Formally Submits Ventripoint's VMS+TM 4.0 System to China's National Medical Products Administration CI
04-01 Ventripoint Diagnostics Ltd. and Health Division of the Montecristo Group Announce Collaboration to Explore Expanded Cardiac Screening, Clinical Research, and AI-Assisted Echocardiography in Costa Rica CI
03-17 Ventripoint Diagnostics Ltd And First Light Health Partner To Bring AI-Powered Cardiac Diagnostics To Indigenous And Remote Communities CI
03-03 Ventripoint Diagnostics Ltd. And LG Consulting Solutions Sign Commercial Agreement For VMS+ Deployment In Northern California CI

Last Transcript: Ventripoint Diagnostics Ltd.

1 day-2.44%
1 week-4.76%
Current month-9.09%
1 month-13.04%
3 months-28.57%
6 months-13.04%
Current year-28.57%
1 week 0.1
Extreme 0.1
0.1
1 month 0.1
Extreme 0.095
0.12
Current year 0.09
Extreme 0.09
0.19
1 year 0.08
Extreme 0.08
0.19
3 years 0.08
Extreme 0.075
0.36
5 years 0.08
Extreme 0.075
0.63
10 years 0.06
Extreme 0.065
0.92
Manager TitleAgeSince
Chief Executive Officer - 2024-02-04
Director of Finance/CFO - 2025-12-02
Chief Executive Officer 78 2010-09-30
Director TitleAgeSince
Chairman 78 2019-12-16
Director/Board Member - 2021-10-24
Director/Board Member - 2021-12-19
Date Insider Type Main position Quantity % Market Cap.
8/1/26 Other

Director

0 0%
8/1/26 Other

Director

0 0%
8/1/26 Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-2.44%-4.76%-9.09%-64.91% 13.87M
+0.27%+6.97%+25.86%+19.39% 233B
+1.36%+8.10%+3.33%-12.35% 154B
+1.16%-3.98%-20.44%+31.92% 134B
+2.03%-2.82%-52.56%-0.08% 73B
+0.98%+2.26%-16.22%-12.49% 52.24B
-0.04%-1.98%+9.73%+18.19% 51.75B
+1.73%+7.05%+30.72%+35.16% 44.91B
+1.49%-0.36%+35.91%+53.26% 40.35B
+1.03%+1.53%-0.53%+8.54% 33.8B
Average +0.76%+1.10%+0.67%+7.66% 81.64B
Weighted average by Cap. +0.98%+3.00%+2.97%+13.70%

Financials

2024 2025
Net sales 95.17K 69.12K 59.21K 55.4K 50.71K 6.61M 96.43K 655K 255K 3.32M 260K 254K 10.99M 180K 131K 112K 105K 95.87K 12.5M 182K 1.24M 483K 6.28M 491K 480K 20.77M
Net income -4.92M -3.57M -3.06M -2.86M -2.62M -342M -4.98M -33.83M -13.19M -172M -13.42M -13.12M -568M -3.2M -2.32M -1.99M -1.86M -1.71M -222M -3.24M -22.01M -8.58M -112M -8.73M -8.54M -369M
Net Debt 1.57M 1.14M 979K 916K 839K 109M 1.6M 10.83M 4.22M 54.95M 4.29M 4.2M 182M 2.56M 1.86M 1.59M 1.49M 1.36M 178M 2.59M 17.58M 6.86M 89.23M 6.97M 6.82M 295M
Logo Ventripoint Diagnostics Ltd.
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.
Employees
-
Date Price Change Volume
26-08-21 $0.1000 -2.44% 103,577
26-08-20 $0.1025 +2.50% 15,046
26-08-19 $0.1000 0.00% 225,900
26-08-18 $0.1000 -4.76% 12,031
26-08-17 $0.1050 0.00% 98,515